Global Artificial Blood and Plasma Market Research Report 2023: Market Trends with Data from 2020-2022, Estimates for 2023, and CAGR Projections through 2028

News provided by

Oct 23, 2023, 10:30 ET

DUBLIN, Oct. 23, 2023 /PRNewswire/ -- The "Artificial Blood and Plasma: Global Markets to 2027" report has been added to ResearchAndMarkets.com's offering.

The artificial blood market was estimated to be $23.9 million in 2022 and is forecasted to grow at a compound annual growth rate (CAGR) of 9.2% to reach a value of $40.5 million through 2028. The market value is low because there are no approved products for artificial blood.

Recently, it has been observed that companies are focusing on developing products that would address the shortcomings of the failed or existing products in the pipeline.

Some of these include the development of freeze-dried HBOCs, Erythromer (from Kalocyte) (which is based on nanocapsule technology), and biosynthetic red blood cells (producing red blood cells from stem cells), being developed by companies such as Erypharma and Red C Biotech. Researchers are also focusing on the development of artificial whole blood by combining three synthetic components: freeze-dried platelet surrogates, freeze-dried red blood cell surrogates, and freeze-dried plasma.

Hemopure is the only marketed product for anemia and is approved in South Africa and Russia and used under an expanded access program in the U.S. Currently, the company doesn't have the infrastructure and funds to produce the product and the company reported no revenue in 2021. In 2022, HemO2life from Hemarina was approved for use as an additive for kidney grafts in the European Union. There are no approved products for routine clinical use in the U.S., which is the primary market.

A similar product for graft preservation is being developed by VirTechBio-OxyBridge-which is in development and anticipated to enter the U.S. market by 2026. There are companies with products in Phase II and Phase II/III development, but the products might not be approved in the forecast period or enter the market by 2028. However, future approvals will help cater to the high unmet need in the market.

Factors leading to the growth of the market are increasing demand for blood transfusions and risks and challenges associated with blood transfusions and shortage of blood supply. Factors such as low rate of approvals, product acceptance, and higher pricing act as barriers to the market. The market is dominated by startup and private biotech companies. Key players in the market include Hemarina, NuvOx Pharmaceuticals, VirTech Bio, and Prolong Pharmaceuticals.

The report includes a discussion of artificial oxygen carrier products. BCC Research analyzes each market segment and provides a forecast for six years. The current report analyzes the market's drivers, challenges, and opportunities. The report also covers market projections for 2028 and the market analysis for key market players.

The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides information on emerging technologies, the impact of COVID-19, product analysis, deals, and investment outlook.

Report Includes

Estimation of market size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Highlights of the market potential and characterization of artificial blood market by product, application, and region
Examination of the key drivers and constraints that will shape the market and discussion on the upcoming market opportunities and areas of focus to forecast the market into various segments and sub-segments
Coverage of recent advances, emerging technologies, and developments of the industry
Evaluation of key industry acquisitions and strategic alliances and market share analysis of the leading suppliers of the industry

Company profiles of major players within the industry, including

Hemarina
VirTechBio
NuvOx Pharma

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

Is There a Problem With Human Blood?
Emerging Needs for Artificial Blood
Artificial Blood Will Be Useful in Dealing With the Risks of Infection
Artificial Blood Will Help to Decrease the Load on the Donor Blood Supply
Artificial Blood is Needed to Deal With Unexpected Demands on the Blood System
Hurdles in the Development of Artificial Blood Products
Ideal Characteristics of Artificial Blood
Artificial Blood Over Human Blood
Applications
Surgeries
Emergency Resuscitation
For Short-Term Use
Where More Effective Than Human Blood
Rejections Due to Religious Beliefs
Challenges in Artificial Blood Development

Chapter 4 Market Dynamics

Drivers
Increasing Demand for Blood Transfusions
Risks and Challenges Associated With Blood Transfusions
Shortage of Blood Supply
Barriers
Low Rate of Product Approvals
Product Acceptance
Product Pricing
Opportunities
Impact of Covid-19

Chapter 5 Artificial Blood by Source

Introduction
Artificial Blood Developed from Human Blood
Artificial Blood Developed from Animal Blood
Artificial Blood Developed Using Recombinant Technology
Surface Modified Hemoglobin
Cross-Linked Hemoglobin
Polymerized Hemoglobin
Encapsulation
Genetically Engineered Recombinant Hemoglobin
Natural Hemoglobin

Chapter 6 Artificial Blood by Type

Introduction
Perfluorocarbon Emulsions
General Characteristics of Perfluorocarbons
Emulsion Selection
Historical Developments of Perfluorocarbon Emulsions
First Generation of Pfcs
Second Generation of Pfcs
Third Generation of Pfcs
Hemoglobin-Based Oxygen Carriers
General Characteristics of Hbocs
Historical Events: Hemoglobin Solutions

Chapter 7 Market Estimation

Introduction
Potential Market for Artificial Blood
Artificial Blood Market, by Source
Blood (Animal/Human)
Synthetic Polymers
Artificial Blood Market, by Type
Hemoglobin-Based Oxygen Carriers
Perfluorocarbon-Based Products
Artificial Blood Market, by Region
North America
Europe
Emerging Markets

Chapter 8 Emerging Technologies and Developments

Overview
Emerging Technologies
Nanocapsule Technology
Stem Cells
Other Ongoing Research for Blood Substitutes

Chapter 9 Product Analysis

Introduction
Product Safety
Product Effectiveness
Product Cost
Legal Implications
Product Analysis of Some of the Products Under Development
Hemopure
Hemo2Life
Hemotech
Nano2 (Ddfpe)
Sanguinate
Vidaphor
Clinical Trials
Product Description of Some of the Products in Preclinical and Early Phase I Stage
Erythromer
Hemoglobin Vesicles
Oxyvita
Oxybridge

Chapter 10 Patent Analysis

Introduction
Fda Regulation
Fda Good Manufacturing Practices and Reporting
Patent Analysis

Chapter 11 Competitive Intelligence

Strategic Developments
Competitive Analysis

Chapter 12 Company Profiles

Aurum Biosciences
Erypharm
Hemoglobin Oxygen Therapeutics LLC.
Hemarina
Kalocyte Inc.
Nano Sanguis S.A
Nuvox Pharma LLC.
Prolong Pharmaceuticals, LLC
Red C Biotech
Virtech Bio

For more information about this report visit https://www.researchandmarkets.com/r/hr5an3

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets